Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Rakovina Therapeutics Inc V.RKV

Alternate Symbol(s):  RKVTF

Rakovina Therapeutics Inc. is a Canada-based biopharmaceutical research company. The Company is focused on the development of new cancer treatments based on novel deoxyribonucleic acid (DNA)-damage response technologies. Its drug development pipeline includes kt-2000AI and kt-3000 series. It is engaged in employing the proprietary Deep Docking AI Platform to rapidly screen billions of potential drug candidates against PARP (kt-2000AI) and other novel DDR targets to generate drug candidates that can be advanced to human trials or developed in collaboration with pharmaceutical partners. Its kt-3000 series represents a novel class of bi-functional small-molecule drug candidates that has been designed to combine inhibition of both poly (ADP)-ribose polymerase (PARP) and histone deacetylase (HDAC) in a single molecule. This novel approach has the potential to overcome treatment resistance and provide clinical benefit to cancer patients.


TSXV:RKV - Post by User

Rakovina Therapeutics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(35)
•••
Post by bmreedon Sep 18, 2024 8:47pm
38 Views
Post# 36230188

Webinar $RKV Executive Chair Jeffrey Bacha Sep 24 @ 1PM ET

Webinar $RKV Executive Chair Jeffrey Bacha Sep 24 @ 1PM ET

Live Webinar - Rakovina Therapeutics (RKV) w/ Executive Chairman Jeffrey Bacha

Tuesday, September 24th at 1PM ET / 10AM PT

Q&A with Radius Research 

Register Here - https://us02web.zoom.us/webinar/register/3017266960381/WN_gKfy7N6HSjGWE1t3HYUVyQ

 

Executive Chairman Jeffery Bacha discusses Rakovina's novel low-cost drug development and partnering strategy targeting DNA-damage response inhibitors.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities